Yu Long, Zhao Hong, Cheng Yongpeng, Fang Zhijian
Department of Hepatobiliary Surgery, Liupanshui People's Hospital, Liupanshui, Guizhou Province, 553000, People's Republic of China.
J Multidiscip Healthc. 2025 Apr 17;18:2193-2200. doi: 10.2147/JMDH.S515125. eCollection 2025.
To analyze the differences in Harmless Acute Pancreatitis Score (HAPS), serum Calcium/Calmodulin-dependent Protein Kinase II (CaMK II) expression, and prognosis among patients with acute pancreatitis (AP) of varying disease severities.
A retrospective analysis was conducted on the clinical data of 103 patients with acute pancreatitis (AP) treated at our hospital between April 2022 and April 2024. According to the revised Atlanta classification and the International Consensus on Definitions (2012), patients were divided into Group A (59 cases, mild cases) and Group B (44 cases, severe cases). The HAPS score was calculated using relevant examination data obtained upon admission. Fasting venous blood samples (5 mL) were collected from all subjects on the morning of the second day after admission, and serum CaMK II expression levels were measured using a double-antibody sandwich method. Patients were followed up for three months from the date of admission to record local complications, systemic complications, and mortality. Receiver operating characteristic (ROC) curves were plotted to analyze the predictive value of HAPS scores and serum CaMK II levels for mild AP and patient prognosis.
HAPS scores and serum CaMK II levels were assessed at admission. Severe cases showed significantly higher HAPS and CaMK II levels vs mild (P<0.05). ROC analysis demonstrated combined detection (AUC=0.902) outperformed individual markers (HAPS=0.827; CaMK II=0.773) in predicting mild AP. Both biomarkers progressively increased with complication severity (local < systemic < death, P<0.05), showing predictive value (AUC>0.6) for prognosis.
HAPS scores and CaMK II expression levels in AP patients show a gradual increase with the severity of the disease, and both can serve as predictive indicators of disease severity and prognosis in AP patients. Moreover, combined detection of these indicators has a higher predictive efficiency than single-item detection.
分析不同疾病严重程度的急性胰腺炎(AP)患者的无害急性胰腺炎评分(HAPS)、血清钙/钙调蛋白依赖性蛋白激酶II(CaMK II)表达及预后的差异。
对2022年4月至2024年4月在我院接受治疗的103例急性胰腺炎(AP)患者的临床资料进行回顾性分析。根据修订的亚特兰大分类和国际定义共识(2012年),将患者分为A组(59例,轻症)和B组(44例,重症)。使用入院时获得的相关检查数据计算HAPS评分。入院后第二天早晨,从所有受试者中采集空腹静脉血样本(5 mL),采用双抗体夹心法检测血清CaMK II表达水平。从入院日期开始对患者进行为期三个月的随访,记录局部并发症、全身并发症和死亡率。绘制受试者工作特征(ROC)曲线,分析HAPS评分和血清CaMK II水平对轻症AP及患者预后的预测价值。
入院时评估HAPS评分和血清CaMK II水平。重症患者的HAPS和CaMK II水平显著高于轻症患者(P<0.05)。ROC分析表明,联合检测(AUC=0.902)在预测轻症AP方面优于单个标志物(HAPS=0.827;CaMK II=0.773)。两种生物标志物均随并发症严重程度逐渐升高(局部<全身<死亡,P<0.05),对预后具有预测价值(AUC>0.6)。
AP患者的HAPS评分和CaMK II表达水平随疾病严重程度逐渐升高,两者均可作为AP患者疾病严重程度和预后的预测指标。此外,这些指标的联合检测比单项检测具有更高的预测效率。